201820172016201520142013201220112010
2018
Kern C, Klausch T, Kreuter F. Tree-based Machine Learning Methods for Survey Research. Forthcoming in Survey Research Methods. 2018. Accepted.
Qendri V, Bogaards JA, Berkhof J. Who Will Benefit From Expanding HPV Vaccination Programs to Boys? JNCI Cancer Spectrum. 2018;2(4):pky076.
Engelhardt EG, Révész D, Tamminga HJ, Punt CJA, Koopman M, Onwuteaka-Philipsen BD, Steyerberg EW, de Vet HCW, Coupé VMH. Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer. BMC Med Inform Decis Mak. 2018;18(1):132.
Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Greuter MJE, Coupé VMH, Canfell K. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. Cancer Epidemiol Biomarkers Prev. 2018;27(12):1450-1461.
Rauh SP, Heymans MW, van der Maaden T, Mehr DR, Kruse RL, de Vet HCW, van der Steen JT. Predicting mortality in a more recent population of nursing home residents with dementia and pneumonia. J Gerontol A Biol Sci Med Sci, 2018. [Epub ahead of print]
Kunst NR, Lindvik H, Carlsen KH, Håland G, Jørgensen E, Lødrup Carlsen KC. Cost-effectiveness of diagnostic algorithms for peanut allergy in children. J Allergy Clin Immunol. 2018. pii: S0091-6749(18)31599-9.
Klausch T, van de Ven P, van de Brug T, van de Wiel M, Berkhof H. Estimating Bayesian Optimal Treatment Regimes for Dichotomous Outcomes using Observational Data. arXiv, 2018.
Qendri, V, Bogaards, JA, Berkhof, J. Pricing of HPV vaccines in European tender-based settings. The European Journal of Health Economics. 2018; 1-10
van der Spek N, Jansen F, Holtmaat K, Vos J, Breitbart W, van Uden-Kraan CF, Tollenaar RAEM, Cuijpers P, Coupé VMH, Verdonck-de Leeuw IM. Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors. Psychooncology. 2018;27(7):1772-1779.
Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Sarfati D, Greuter MJE, Coupé VMH, Canfell K. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Int J Cancer. 2018;143(2):269-282.
Wolff HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, Twisk JW, Lagerwaard FJ, Senan S, El Sharouni SY, Schramel FMNH, Coupé VMH. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. pii: S1556-0864(18)30083-2.
Bronzwaer MES, Greuter MJE, Bleijenberg AGC, IJspeert JEG, Dekker E, Coupé VMH. Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening. BMC Cancer. 2018;18(1):465.
van den Boorn HG, Engelhardt EG, van Kleef J, Sprangers MAG, van Oijen MGH, Abu-Hanna A, Zwinderman AH, Coupé VMH, van Laarhoven HWM. Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis. PLoS One. 2018;13(2):e0192310.
Rauh SP, Rutters F, van der Heijden AAWA, Luimes T, Alssema M, Heymans MW, Magliano DJ, Shaw JE, Beulens JW, Dekker JM: External validation of a tool predicting 7-year-risk of developing cardiovascular disease, type 2 diabetes or chronic kidney disease. J Gen Intern Med, 2018;33(2):182-188.
Ruijgrok C, Dekker JM, Beulens JW, Brouwer IA, Coupé VMH, Heymans MW, Sijtsma FPC, Mela DJ, Zock PL, Olthof MR, Alssema M. Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study. Diabetologia. 2018;61(1):93-100.
2017
van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol. 2017;74(12):1481-1491.
Bosmans JE, Coupé VMH, Knottnerus BJ, Geerlings SE, Moll van Charante EP, Ter Riet G. Cost-effectiveness of different strategies for diagnosis of uncomplicated urinary tract infections in women presenting in primary care. PLoS One. 2017;12(11):e0188818.
Kolovos S, Bosmans JE, Riper H, Chevreul K, Coupé VMH, van Tulder MW. Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review. PharmacoEconomics – Open. 2017;1(3):149–165.
Engelhardt EG, Révész D, Tamminga HJ, Punt CJA, Koopman M, Onwuteaka-Philipsen BD, Steyerberg EW, Jansma IP, De Vet HCW, Coupé VMH. Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer. 2017. pii: S1533-0028(17)30148-2. [Epub ahead of print]
Révész D, Engelhardt EG, Tamminga JJ, Schramel FMNH, Onwuteaka-Philipsen BD, van de Garde EMW, Steyerberg EW, Jansma EP, De Vet HCW, Coupé VMH. Decision support systems for incurable non-small cell lung cancer: a systematic review. BMC Med Inform Decis Mak. 2017;17(1):144.
Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupé VMH. Screening for Colorerectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Ann Intern Med. 2017;167(8):544-554.
Witte BI, Berkhof J, Jonker MA. An EM Algorithm for Nonparametric Estimation of the Cumulative Incidence Function from Repeated Imperfect Test Results. Stat Med. 2017;36(21):3412-3421.
Qendri V, Bogaards JA, Berkhof J. Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. J Infect Dis. 2017;216(2):210-219.
Greuter MJ, Schouten CS, Castelijns JA, de Graaf P, Comans EF, Hoekstra OS, de Bree R, Coupé VM. Cost-Effectiveness of Response Evaluation in Patients with Advanced Oropharyngeal Cancer using 18F-FDG-PET-CT and/or Diffusion-Weighted MRI. BMC Cancer. 2017;17(1):256.
2016
Jansen F, Krebber AM, Coupé VM, Cuijpers P, de Bree R, Becker-Commissaris A, Smit EF, van Straten A, Eeckhout GM, Beekman AT, Leemans CR, Verdonck-de Leeuw IM. Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer. J Clin Oncol. 2016;35(3):314-324
Coupé VMH, van Hooff ML, de Kleuver M, Steyerberg EW, Ostelo RWJG. Decision support tools in low back pain. Best Pract Res Clin Rheumatol. 2016;30(6):1084-1097.
van Amerongen RA, Retèl VP, Coupé VM, Nederlof PM, Vogel MJ, van Harten WH. Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis. Ecancermedicalscience. 2016;10:684. eCollection 2016.
Greuter MJ, Berkhof J, Canfell K, Lew JB, Dekker E, Coupé VM. Resilience of a FIT screening programme against screening fatigue: a modelling study. BMC Public Health. 2016;16(1):1009.
Vink MA, Berkhof J, van de Kassteele J, van Boven M, Bogaards JA. A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization. PLoS One. 2016;11(8):e0161109.
Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM. The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. Br J Radiol. 2016;89(1063):20150910.
Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924.
Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, Dekker E, Meijer GA, Coupé VM. Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway. Cancer Epidemiol Biomarkers Prev. 2016;25(1):135-44.
van der Meijde E, van den Eertwegh AJ, Linn SC, Meijer GA, Fijneman RJ, Coupé VM. The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care. Cancer Inform. 2016;15:115-27.
van der Linden N, Bongers ML, Coupé VM, Smit EF, Groen HJ, Welling A, Schramel FM, Uyl-de Groot CA. Costs of non-small cell lung cancer in the Netherlands. Lung Cancer. 2016;91:79-88.
Bongers ML, de Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Coupé VM. Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity. Med Decis Making. 2016;36(1):86-100.
Bongers ML, De Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Coupé VM. Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity. Med Decis Making. 2016;36(1):86-100.
2015
Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016.
Bongers ML, Coupé VM, De Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA. Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation. Int J Radiat Oncol Biol Phys. 2015;91(4):857-65.
de Baaij LR, Berkhof J, van de Water JM, Sieniawski MK, Radersma M, Verbeek WH, Visser OJ, Oudejans JJ, Meijer CJ, Mulder CJ, Lennard AL, Cillessen SA. A new and validated clinical prognostic model (EPI) for Enteropathy Associated T-cell Lymphoma. Clin Cancer Res. 2015;21(13):3013-9.
Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Snijders PJ, Meijer CJ, Ronco G. The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomarkers Prev. 2015;24(1):111-8.
Vink MA, Bogaards JA, Meijer CJ, Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? Int J Cancer. 2015;137(2):420-7.
2014
Greuter MJ, Xu XM, Lew JB, Dekker E, Kuipers EJ, Canfell K, Meijer GA, Coupé VM. Modeling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA). Risk Anal. 2014;34(5):889-910.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014 8;383(9916):524-32.
Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA, Snijders PJ, Meijer CJ, Berkhof J. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev. 2014;23(1):55-63.
2013
Haloua MH, Krekel NM, Coupé VM, Bosmans JE, Lopes Cardozo AM, Meijer S, van den Tol MP. Ultrasound-guided surgery for palpable breast cancer is cost-saving: results of a cost-benefit analysis. Breast. 2013;22(3):238-43.
Lin CW, Uegaki K, Coupé VM, Kerkhoffs GM, van Tulder MW. Economic evaluations of diagnostic tests, treatment and prevention for lateral ankle sprains: a systematic review. Br J Sports Med. 2013;47(18):1144-9.
Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013;31 Suppl 7:H71-9.
Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161-9.
Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med. 2013;11:23.
van de Ven PM, Berkhof J. Non-inferiority and superiority tests for partially matched data when a constraint is placed on the number of new tests. Stat Med. 2013;32(15):2515-28.
Flach GB, Leemans CR, de Bree R, Witte BI. Reply to Letter to the editor – is no difference always a good thing? Panayiotis A. Kyzas. Oral Oncol. 2013;49(9):e29-31.
Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, Witte BI, de Bree R, Doornaert P, Langendijk JA, Leemans CR. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol. 2013;49(5):443-8.
van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013;72(12):1920-6.12
2012
Coupé VM, Bogaards JA, Meijer CJ, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine. 2012;30(10):1813-22.
Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 2012;30(1):17-34.
Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130(3):602-10.
Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157-67.
Bleeker MC, Meijer CJ, Berkhof J. Follow-up after treatment for cervical intraepithelial neoplasia. BMJ. 2012;345:e7186.
Meijer CJ, Berkhof J. Screening: Cervical cancer–should we abandon cytology for screening? Nat Rev Clin Oncol. 2012;9(10):558-9.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88.
Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske DP, Postma TJ. MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology. 2012;54(6):539-46.
Janssen EH, van de Ven PM, Terluin B, Verhaak PF, van Marwijk HW, Smolders M, van der Meer K, Penninx BW, van Hout HP. Recognition of anxiety disorders by family physicians after rigorous medical record case extraction: results of the Netherlands Study of Depression and Anxiety. Gen Hosp Psychiatry. 2012;34(5):460-7.
2011
Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med. 2011;8(12):e1001147.
Bogaards JA, Coupé VM, Meijer CJ, Berkhof J. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine. 2011;29(48):8929-36.
Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22(4):505-15.
2010
Berkhof J, Coupé VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer. 2010;127(9):2147-58.
Bogaards JA, Xiridou M, Coupé VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol. 2010;171(7):817-25.